Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Canadian Guidelines for Controlled Pediatric Donation After Circulatory Determination of Death-Summary Report.
Weiss MJ, Hornby L, Rochwerg B, van Manen M, Dhanani S, Sivarajan VB, Appleby A, Bennett M, Buchman D, Farrell C, Goldberg A, Greenberg R, Singh R, Nakagawa TA, Witteman W, Barter J, Beck A, Coughlin K, Conradi A, Cupido C, Dawson R, Dipchand A, Freed D, Hornby K, Langlois V, Mack C, Mahoney M, Manhas D, Tomlinson C, Zavalkoff S, Shemie SD. Weiss MJ, et al. Among authors: barter j. Pediatr Crit Care Med. 2017 Nov;18(11):1035-1046. doi: 10.1097/PCC.0000000000001320. Pediatr Crit Care Med. 2017. PMID: 28925929 Free PMC article.
An Adverse Reaction in the Pediatric Sleep Laboratory.
Reppucci D, Medin D, Al-Saleh S, Smith MJ, Barter J, Amin R. Reppucci D, et al. Among authors: barter j. Can Respir J. 2016;2016:9712579. doi: 10.1155/2016/9712579. Epub 2016 Mar 29. Can Respir J. 2016. PMID: 27445573 Free PMC article.
An adverse reaction in a pediatric sleep laboratory.
Reppucci D, Reppucci D, Medin D, Smith MJ, Barter J, Amin R. Reppucci D, et al. Among authors: barter j. Can Respir J. 2015 Oct 1:17138. Online ahead of print. Can Respir J. 2015. PMID: 26426359 No abstract available.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Arend RC, Monk BJ, Shapira-Frommer R, Haggerty AF, Alvarez EA, Amit A, Alvarez Secord A, Muller C, Casado Herraez A, Herzog TJ, Tewari KS, Cohen JG, Huang M, Yachnin A, Holeman LL, Ledermann JA, Rachmilewitz Minei T, Buyse M, Fain Shmueli S, Lavi M, Harats D, Penson RT; OVAL/GOG-3018 Investigators. Arend RC, et al. J Clin Oncol. 2024 Jan 10;42(2):170-179. doi: 10.1200/JCO.22.02915. Epub 2023 Oct 31. J Clin Oncol. 2024. PMID: 37906726 Clinical Trial.
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW. Holloway RW, et al. Among authors: barter j. Int J Gynecol Cancer. 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. Int J Gynecol Cancer. 2023. PMID: 37666539 Clinical Trial.
126 results